Currently, it is more often used as combination therapy with BRAF inhibitors (Table 3) for the treatment of unresectable or metastatic melanoma harboring BRAF V600E and/or V600K mutation (Roskoski, 2018). This evidence concerns the gene BRAF and metastatic melanoma.